Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DUT | P33316 | 2/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12729559 | 0.85 | DNMT1 (0.37) | — | |
| SCHEMBL12729521 | 0.82 | DUT (0.45) | P2RY2P2RY6P2RY4POLBDUT | |
| SCHEMBL12369380 | 0.79 | P2RY2 (0.46) | P2RY2P2RY6P2RY4POLB | |
| SCHEMBL12369382 | 0.79 | P2RY12 (0.52) | P2RY2P2RY6POLB | |
| SCHEMBL12729595 | 0.77 | POLB (0.45) | P2RY2P2RY6P2RY4POLBTRPM2 | |
| SCHEMBL14183915 | 0.77 | P2RY12 (0.53) | P2RY2P2RY6POLB | |
| SCHEMBL12729634 | 0.76 | P2RY2 (0.45) | P2RY2P2RY6P2RY4POLB | |
| SCHEMBL17833852 | 0.76 | P2RY6 (0.39) | P2RY2P2RY6P2RY4POLBDUT | |
| SCHEMBL12729564 | 0.75 | P2RY6 (0.38) | P2RY2P2RY6P2RY4DUTPOLA1 | |
| SCHEMBL12369368 | 0.74 | P2RY12 (0.52) | P2RY2P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | DUT, NT5C2, NUDT21 | P2RY2 249/4885P2RY6 186/4885P2RY4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.